What's available for data on their use to begin with?

Yeah, so obviously we've had intramuscular epinephrine for years, and that's both via autoinjector, which is the one we give to patients, and then syringin needle.

And those two routes do have different pharmacokinetics.

The syringin needle gets into the blood a little slower and has a slower peak, whereas the autoinjector gets in pretty quickly, has a quick peak, and then tails off a little quicker than the syringin needle.

So regulatory agencies, knowing that we have been using those for years, have used those almost as a standard of care, the bar, the standard of care.

And therefore, newer routes have had to say, if we can... mimic those routes, meaning bracket between those routes, then the regulatory agencies have said that is good enough to lead to approval for the treatment of acute allergic reactions or anaphylaxis.

So newer routes have been studied for years.

Can we talk about that? Because it is bracketed, but one is different than the other.